Show simple item record

dc.contributor.authorAuthorAguilera, Ximena
dc.contributor.authorAuthorGonzalez, Claudia
dc.contributor.authorAuthorApablaza, Mauricio
dc.contributor.authorAuthorRubilar, Paola
dc.contributor.authorAuthorIcaza, Gloria
dc.contributor.authorAuthorRamírez-Santana, Muriel
dc.contributor.authorAuthorPérez, Claudia
dc.contributor.authorAuthorCortes, Lina Jimena
dc.contributor.authorAuthorNúñez-Franz, Loreto
dc.contributor.authorAuthorQuezada-Gaete, Rubén
dc.contributor.authorAuthorCastillo-Laborde, Carla
dc.contributor.authorAuthorCorrea, Juan
dc.contributor.authorAuthorSaid, Macarena
dc.contributor.authorAuthorHormazábal, Juan
dc.contributor.authorAuthorVial, Cecilia
dc.contributor.authorAuthorVial, Pablo
dc.contributor.otherCareerArquitecturaes
dc.date.accessionedDate Accessioned2022-08-23T14:18:54Z
dc.date.availableDate Available2022-08-23T14:18:54Z
dc.date.issuedDate Issued2022-06-23
dc.identifier.citationReferencia BibliográficaVaccines 10(7),7 p.
dc.identifier.issnISSN2076-393X
dc.identifier.uriURIhttp://repositorio.udla.cl/xmlui/handle/udla/1127
dc.identifier.uriURIhttps://www.mdpi.com/journal/vaccines
dc.description.abstractAbstractChile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access.es
dc.format.extentdc.format.extent7 páginas
dc.format.extentdc.format.extent588.3Kb
dc.format.mimetypedc.format.mimetypePDF
dc.language.isoLanguage ISOen
dc.publisherPublisherMDPI
dc.rightsRightsCreative Commons Attribution (CC BY)
dc.sourceSourcesVaccines
dc.subjectSubjectSinovac CoronaVaces
dc.subjectSubjectBNT162b2es
dc.subjectSubjectAZD1222es
dc.subjectSubjectELISAes
dc.subjectSubjectCross-sectionales
dc.subject.lcshdc.subject.lcshCOVID-19 (Disease)
dc.subject.lcshdc.subject.lcshVaccines
dc.titleTitleImmunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chilees
dc.typeDocument TypeArtículoes
dc.udla.catalogadordc.udla.catalogadorCBM
dc.udla.indexdc.udla.indexSCOPUS
dc.identifier.doidc.identifier.doihttps://doi.org/10.3390/vaccines10071002
dc.udla.privacidaddc.udla.privacidadDocumento públicoes


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record